Möchten Sie immer auf dem neuesten Stand bleiben?

Westford, USA, Oct. 11, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Additive Manufacturing Market will reach a value of USD 91.59 Billion by 2031, with a CAGR of 20.8% during the...

Segments (EURm)Q3/24Q3/23yoy9m/249m/23yoySupermarkets149.5153.5-2.6%446.3455.2-1.9%Department stores21.523.9-9.7%71.075.6-6.1%Cars50.751.1-0.8%149.6148.60.7%Security...

Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1 Data showed...

Los Angeles, Oct. 08, 2024 (GLOBE NEWSWIRE) -- According to Precedence Research, the global amino acids market size will hit USD 33.72 billion in 2025 and is expected to surpass around USD 69.11...

PRESS RELEASE Loudéac, 3 October 2024 FIRST-HALF 2024 RESULTS Return to growth in Q2 2024Gross margin holds up well at 32.4% of revenueOperating profitability bottoming out H2 2024 OUTLOOK ...

With this approval, Yuvanci® is the only single tablet combination therapy for treatment for patients with PAH in Europe Johnson & Johnson’s comprehensive PAH portfolio now covers all...

Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase 3 CEPHEUS study results presented in...

Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific...

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) --...

Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk...